Kashiv BioSciences Receives Health Canada Validation for Omalizumab Biosimilar
Kashiv BioSciences has announced that Health Canada has validated and accepted the marketing authorization application for ADL-018, a proposed biosimilar to XOLAIR® (omalizumab). Omalizumab is used to treat various conditions, including asthma, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and IgE-mediated food allergies. The acceptance of this application marks a significant regulatory milestone for Kashiv's biosimilars portfolio, potentially expanding access to cost-effective biologic therapies in Canada. 
